The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2025 | Advancements in stage II-III NSCLC management: neoadjuvant chemo-IO and postoperative strategies
Gerry Hanna, MBBCh, PhD, MRCP, FRCR, FRANZCR, Trinity College Dublin, Dublin, Ireland, discusses key developments in the management of stage 2 and stage 3 non-small cell lung cancer (NSCLC), particularly the role of neoadjuvant and perioperative chemoimmunotherapy. He highlights ongoing debates on defining operability, optimal post-treatment strategies for patients who progress after neoadjuvant therapy, and the evolving role of postoperative radiotherapy in light of improved techniques. This interview took place at the BTOG 2025 congress in Belfast, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
